AIMS: We prospectively studied the efficacy, incidence of adverse drug reactions and withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting of care-as-usual. METHODS: In this prospective case series study, from outpatient medical records a standard dataset was collected including patient and disease characteristics, data on leflunomide use and adverse drug reactions. RESULTS: During the study period 136 rheumatoid arthritis patients started leflunomide. Median (range) follow-up duration was 317 (11-911) days. Sixty-five percent of patients experienced at least one adverse drug reaction related to leflunomide. During follow-up 76 patients (56%) withdrew from leflunomide treatment, mainly because of adverse drug reactions (29%) or lack of efficacy (13%). The overall incidence density for withdrawal from leflunomide was 56.2 per 100 patient-years. Complete data for calculating efficacy using a validated disease activity score on 28 joints (DAS(28)) was available for 48, 36, and 35% of patients at 2, 6, and 12 months follow-up, respectively. Within a 12-month period after start of leflunomide treatment 76% of the evaluable patients were classified as moderate or good responders according to the DAS(28) response criteria. CONCLUSIONS: In the setting of care-as-usual, rheumatoid arthritis patients starting leflunomide frequently experienced adverse drug reactions. More than half of the patients withdrew from leflunomide treatment within a year after start of leflunomide treatment, mainly because of adverse drug reactions.
AIMS: We prospectively studied the efficacy, incidence of adverse drug reactions and withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting of care-as-usual. METHODS: In this prospective case series study, from outpatient medical records a standard dataset was collected including patient and disease characteristics, data on leflunomide use and adverse drug reactions. RESULTS: During the study period 136 rheumatoid arthritispatients started leflunomide. Median (range) follow-up duration was 317 (11-911) days. Sixty-five percent of patients experienced at least one adverse drug reaction related to leflunomide. During follow-up 76 patients (56%) withdrew from leflunomide treatment, mainly because of adverse drug reactions (29%) or lack of efficacy (13%). The overall incidence density for withdrawal from leflunomide was 56.2 per 100 patient-years. Complete data for calculating efficacy using a validated disease activity score on 28 joints (DAS(28)) was available for 48, 36, and 35% of patients at 2, 6, and 12 months follow-up, respectively. Within a 12-month period after start of leflunomide treatment 76% of the evaluable patients were classified as moderate or good responders according to the DAS(28) response criteria. CONCLUSIONS: In the setting of care-as-usual, rheumatoid arthritispatients starting leflunomide frequently experienced adverse drug reactions. More than half of the patients withdrew from leflunomide treatment within a year after start of leflunomide treatment, mainly because of adverse drug reactions.
Authors: V Strand; S Cohen; M Schiff; A Weaver; R Fleischmann; G Cannon; R Fox; L Moreland; N Olsen; D Furst; J Caldwell; J Kaine; J Sharp; F Hurley; I Loew-Friedrich Journal: Arch Intern Med Date: 1999-11-22
Authors: M E Weinblatt; J M Kremer; J S Coblyn; A L Maier; S M Helfgott; M Morrell; V M Byrne; M V Kaymakcian; V Strand Journal: Arthritis Rheum Date: 1999-07
Authors: P Emery; F C Breedveld; E M Lemmel; J P Kaltwasser; P T Dawes; B Gömör; F Van Den Bosch; D Nordström; O Bjorneboe; R Dahl; K Horslev-Petersen; A Rodriguez De La Serna; M Molloy; M Tikly; C Oed; R Rosenburg; I Loew-Friedrich Journal: Rheumatology (Oxford) Date: 2000-06 Impact factor: 7.580
Authors: M C Kraan; R J Reece; E C Barg; T J Smeets; J Farnell; R Rosenburg; D J Veale; F C Breedveld; P Emery; P P Tak Journal: Arthritis Rheum Date: 2000-08
Authors: E N van Roon; M Hoekstra; H Tobi; T L Th A Jansen; H J Bernelot Moens; J R B J Brouwers; M A F J van de Laar Journal: Br J Clin Pharmacol Date: 2005-09 Impact factor: 4.335
Authors: E N van Roon; T L T A Jansen; M A F J van de Laar; M Janssen; J P Yska; R Keuper; P M Houtman; J R B J Brouwers Journal: Ann Rheum Dis Date: 2004-09-02 Impact factor: 19.103
Authors: Monica C Serra; Carolyn J Accardi; Chunyu Ma; Younja Park; ViLinh Tran; Dean P Jones; Charlene E Hafer-Macko; Alice S Ryan Journal: J Stroke Cerebrovasc Dis Date: 2019-10-25 Impact factor: 2.136
Authors: Michael D Wiese; Matthew Schnabl; Catherine O'Doherty; Llewellyn D Spargo; Michael J Sorich; Leslie G Cleland; Susanna M Proudman Journal: Arthritis Res Ther Date: 2012-07-12 Impact factor: 5.156